8-K: Anebulo Pharmaceuticals to Delist from Nasdaq

Anebulo Pharmaceuticals announced its decision to voluntarily delist from Nasdaq and deregister with the SEC, citing high costs, while reporting Q2 FY26 financial results.

Summary

• The Board approved the voluntary delisting of common stock from The Nasdaq Capital Market and subsequent voluntary deregistration with the U.S. Securities and Exchange Commission (SEC) to terminate and suspend reporting obligations.
• Anebulo notified Nasdaq of its intention to voluntarily delist shares on February 6, 2026, with an intent to file a Form 25 with the SEC on or about February 17, 2026.
• The delisting from Nasdaq is expected to become effective on February 27, 2026, 10 days after filing the Form 25.
• Anebulo intends to file a Form 15 with the SEC on or about February 27, 2026, certifying fewer than 300 shareholders of record, which will immediately suspend its obligation to file periodic reports.
• The decision was based on the belief that the costs associated with being an SEC reporting company and Nasdaq-listed outweigh the benefits, including significant legal, audit, and management time expenses.
• Total operating expenses for the second quarter of fiscal 2026 were $2.6 million, consistent with $2.6 million in the same period of fiscal 2025.
• Net loss in the second quarter of fiscal 2026 was $2.0 million, or $(0.05) per share, an improvement from a net loss of $2.5 million, or $(0.09) per share, in the second quarter of fiscal 2025.
• Cash and cash equivalents were $9.0 million as of December 31, 2025, with access to an additional $3.0 million through a Loan Agreement.
• The company's lead product candidate, selonabant (ANEB-001), is a potent CB1 receptor antagonist for acute cannabis-induced toxicity.
• Anebulo is prioritizing the advancement of a selonabant IV formulation as a potential treatment for pediatric patients with acute cannabis-induced toxicity, believing it offers a faster timeline to approval.
• A Phase 1 SAD study of IV selonabant was initiated in September 2025.
• An observational study in Emergency Departments for cannabis toxicity is ongoing and being amended to focus on pediatric patients.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a significantly negative development for public shareholders due to the impending delisting and deregistration, which will severely impact liquidity and transparency, despite some progress in clinical development and reduced net loss.

Positives

• Net loss decreased to $2.0 million (or $(0.05) per share) in Q2 FY26 from $2.5 million (or $(0.09) per share) in Q2 FY25.
• Oral selonabant successfully blocked or reversed key CNS effects of THC and was well tolerated in a Phase 2 proof-of-concept study.
• Selonabant is protected by three issued US patents and rights to six additional patent applications, two pending Patent Cooperation Treaty (PCT) applications, and additional international patent applications.
• The company is prioritizing the selonabant IV formulation for pediatric patients, which is believed to offer a faster timeline to approval.
• A Phase 1 SAD study of IV selonabant was initiated in September 2025.

Negatives

• The company's board approved the voluntary delisting of its common stock from Nasdaq and subsequent voluntary deregistration with the SEC.
• Following delisting, any trading in common stock would only occur in privately negotiated sales and potentially on the over-the-counter market, significantly reducing liquidity and transparency for shareholders.
• The decision to delist is based on the belief that the costs of being an SEC reporting company outweigh the benefits, suggesting financial pressures or a strategic shift away from public market advantages.
• Cash and cash equivalents decreased to $9.0 million as of December 31, 2025, from $11.6 million as of June 30, 2025.

Risks

• Ability to pursue regulatory strategy.
• Ability of selonabant to be a potential treatment for pediatric patients with cannabis-induced poisoning.
• Ability of selonabant to rapidly reverse key symptoms of cannabis toxicity.
• Ability of a selonabant IV formulation as a potential treatment for pediatric patients with acute cannabis-induced toxicity.
• Ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements.
• Ability to obtain or maintain the capital or grants necessary to fund research and development activities.
• Ability to complete clinical trials on time and achieve desired results and benefits as expected.
• Regulatory limitations relating to the ability to promote or commercialize product candidates for specific indications.
• Acceptance of product candidates in the marketplace and the successful development, marketing or sale of products.
• Ability to maintain license agreements.
• Continued maintenance and growth of patent estate.
• Ability to retain key employees.
• Ability to successfully complete the voluntary delisting from Nasdaq and the deregistration of common stock.

Future Outlook

Anebulo Pharmaceuticals anticipates selonabant will rapidly reverse key symptoms of acute cannabis-induced toxicity. The company is prioritizing the advancement of a selonabant IV formulation for pediatric patients, believing it offers a faster timeline to approval compared to the adult oral product. The company also expects to complete its voluntary delisting from Nasdaq and deregistration with the SEC, suspending its reporting obligations.

Management Comments

• The Board believes that the cost of being an SEC reporting company outweighs the benefits.
• The burdens associated with operating as a registered public company listed on Nasdaq outweigh any advantages to the Company and the holders of its common stock.
• The Board's decision was based on the careful review of numerous factors, including the potential for eliminating the significant costs associated with preparing and filing periodic reports with the SEC and the legal, audit and other expenses associated with being a public reporting company listed on Nasdaq, as well as the substantial costs and demands on management's time under the Sarbanes-Oxley Act of 2002, SEC rules and Nasdaq listing standards.
• Prioritizing the advancement of a selonabant IV formulation as a potential treatment for pediatric patients with acute cannabis-induced toxicity, which it believes offers the potential for a faster timeline to approval relative to the adult oral product.

Industry Context

StockSavvy.ai notes that Anebulo's decision to delist from Nasdaq and deregister with the SEC is a significant strategic shift, often seen in smaller clinical-stage pharmaceutical companies facing high compliance costs relative to their market capitalization or funding stage. This move allows the company to conserve capital and management resources, redirecting them towards core drug development, specifically the selonabant IV formulation for pediatric cannabis toxicity, a niche but potentially high-need area. While reducing administrative burden, it also significantly limits access to public capital markets and investor liquidity, which is a trade-off for a company still in clinical development.

Comparison to Industry Standards

• StockSavvy.ai observes that the delisting decision is a departure from standard practices for companies with active clinical programs seeking broad investor access. While some smaller biotechs may opt for private funding or alternative listing venues, a full deregistration from SEC reporting is a drastic step that typically signals a pivot away from public market engagement.
• For example, larger clinical-stage companies like Moderna or BioNTech maintained public listings throughout their development to facilitate capital raises and investor visibility.
• Anebulo's focus on pediatric cannabis toxicity with an IV formulation is a specific therapeutic area, but without a public listing, direct comparisons to peer companies in terms of market valuation or funding strategies become challenging.
• The financial metrics, while showing a reduced net loss, are typical of a clinical-stage company with no revenue, and the cash position of $9.0 million (plus $3.0 million access) is modest for ongoing drug development without public market access.

Stakeholder Impact

• Shareholders: Significant negative impact due to loss of liquidity, transparency, and public market access. Trading will be limited to privately negotiated sales and potentially OTC market.
• Management: Reduced administrative burden and demands on time associated with SEC reporting and Nasdaq listing standards.
• Company: Potential for eliminating significant costs associated with public reporting, allowing resources to be redirected to drug development.

Next Steps

• File Form 25 with the SEC on or about February 17, 2026, for delisting.
• Delisting from Nasdaq expected to become effective on February 27, 2026.
• File Form 15 with the SEC on or about February 27, 2026, to suspend reporting obligations.
• Continue with efforts to maximize value from lead product candidate, selonabant.
• Continue Phase 1 SAD study of IV selonabant.
• Amend ongoing observational study in Emergency Departments to focus on pediatric patients.

Key Dates

Recommendation

The decision to voluntarily delist from Nasdaq and deregister with the SEC is a highly negative event for current public shareholders. This action will drastically reduce liquidity, transparency, and the ability to easily trade shares, effectively turning a publicly traded stock into a privately held security with limited market access. While the company cites cost savings, this move signals a retreat from public markets, making it an unattractive investment for most institutional and retail investors. The long-term prospects of the drug candidate, while potentially promising, are now obscured by the lack of public reporting and market access, justifying a strong sell recommendation for existing shareholders to exit before liquidity evaporates.

Keywords

Anebulo Pharmaceuticals, ANEB, Nasdaq delisting, SEC deregistration, cannabis-induced toxicity, selonabant, pharmaceuticals, clinical-stage, drug development, acute cannabinoid intoxication, pediatric cannabis poisoning, Form 8-K, financial results